Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Countries and Company Analysis, 2025-2033" report has been added ...
Could the third time be the charm for an oral HIF-PH inhibitor in the U.S.? GlaxoSmithKline certainly hopes so, with its potential first-in-class medicine now officially up for a decision at the FDA ...
In the race for novel oral drugs to treat anemia of chronic kidney disease, AstraZeneca and FibroGen’s roxadustat held the front-runner position for quite some time. But as that program has now ...
With the NDA target date of October approaching for roxadustat, Fibrogen Inc.'s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia in chronic kidney disease (CKD), watchers of ...
August 4th 2020EP. 14: Future Treatment of Anemia in CKD: Impact of HIF Stabilizers August 4th 2020EP. 15: Future Management of Anemia in CKD ...
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe ...
Doctors diagnose anemia when a blood test shows hemoglobin levels of less than 13.5 grams per deciliter (g/dL) for men or 12.0 g/dL for women. If you have slightly higher red blood cell counts and ...
While mild anemia is generally treatable, some severe forms, like thalassemia and aplastic anemia, can lead to life-threatening complications if untreated due to the body’s organs not receiving enough ...
Thalassemia is a genetic condition that can lead to many complications, with anemia being one of the hallmarks. Treatments can help keep anemia from developing. Thalassemia and anemia are both red ...
TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback